CTGov Compliance My Organizations

Compliance Rate

Compliance Rate 0%

Compliant submissions 0

Incompliant submissions 0

Total trials 0

My Organizations' Clinical Trials

Showing 75 of 275 entries

View as:

Non-interventional Study to Assess Adherence to Treatment for Patients With RMS (MAIN-MS)

Phase: N/A Priority: Normal

NCT ID: NCT02921035 Org: User:

Start: 06/30/16 End: 07/27/20 Due: 07/27/21

An Active-controlled, Clinical Trial to Assess Central Hemodynamic Effects of Bisoprolol in Hypertensive Patients (Central Hemodynamic Assessment Measured in Patient With HypertensION [CHAMPION])

Phase: N/A Priority: Normal

NCT ID: NCT01079962 Org: User:

Start: 12/31/09 End: 10/31/11 Due: 10/31/12

Pharmacokinetics in Subjects With Renal Impairment

Phase: N/A Priority: Normal

NCT ID: NCT01504165 Org: User:

Start: 01/31/12 End: 04/30/12 Due: 04/30/13

A Japanese Phase 1 Trial of TH-302 in Subjects With Solid Tumors and Pancreatic Cancer

Phase: N/A Priority: Normal

NCT ID: NCT01833546 Org: User:

Start: 04/18/13 End: 01/25/16 Due: 01/25/17

Transition to Rebif New Formulation

Phase: N/A Priority: Normal

NCT ID: NCT00619307 Org: User:

Start: 07/31/07 End: 04/30/08 Due: 04/30/09

Trial of MSC1936369B in Subjects With Solid Tumors

Phase: N/A Priority: Normal

NCT ID: NCT00982865 Org: User:

Start: 12/31/07 End: 04/30/16 Due: 04/30/17

REbif FLEXible Dosing in Early Multiple Sclerosis (MS)

Phase: N/A Priority: Normal

NCT ID: NCT00404352 Org: User:

Start: 11/30/06 End: 07/31/11 Due: 07/31/12

First-in-Human Trial of Anti-ADAMTS-5 Nanobody in Healthy Volunteers

Phase: N/A Priority: Normal

NCT ID: NCT03224702 Org: User:

Start: 09/04/17 End: 08/06/18 Due: 08/06/19

Long-term Follow-Up of Patients Who Participated in Study 27025 (REFLEX)

Phase: N/A Priority: Normal

NCT ID: NCT00813709 Org: User:

Start: 12/31/08 End: 09/30/13 Due: 09/30/14

Safety, Tolerability and Adherence With Rebif® New Formulation in Real Life Settings (STAR)

Phase: N/A Priority: Normal

NCT ID: NCT01080027 Org: User:

Start: 10/31/08 End: 06/30/11 Due: 06/30/12

Assessment of Patient Use of a New Device: RebiSmart

Phase: N/A Priority: Normal

NCT ID: NCT01195870 Org: User:

Start: 07/31/09 End: 10/31/10 Due: 10/31/11

A Trial to Evaluate the Correlation Between Spontaneous Catch-up Growth, Clinical Response to Saizen (Recombinant Human Growth Hormone, r-hGH) and Gene Expression Profiling in Children Small for Gestational Age (SGA)

Phase: N/A Priority: Normal

NCT ID: NCT01067352 Org: User:

Start: 02/29/04 End: 07/31/09 Due: 07/31/10

An Observational Study to Evaluate Quality of Life (QoL) and Influence of Cognitive Status on QoL in Patients With Relapsing-Remitting Multiple Sclerosis (RRMS) During 2 Years Treatment With Rebif New Formulation (RNF)

Phase: N/A Priority: Normal

NCT ID: NCT01110993 Org: User:

Start: 11/30/10 End: 09/30/13 Due: 09/30/14

Study of Tecemotide (L-BLP25) in Subjects With Slowly Progressive Multiple Myeloma With no Symptoms and Who Have Had no Chemotherapy

Phase: N/A Priority: Normal

NCT ID: NCT01094548 Org: User:

Start: 01/31/08 End: 03/31/12 Due: 03/31/13

Tolerability of Rebif® (Interferon-beta 1-A) Therapy in Korean Patients With Multiple Sclerosis

Phase: N/A Priority: Normal

NCT ID: NCT01074346 Org: User:

Start: 08/31/08 End: 11/30/11 Due: 11/30/12

A Korean Post-marketing Surveillance Study on Erbitux® in Patients With Metastatic Colorectal Cancer Refractory to Irinotecan-containing Treatment

Phase: N/A Priority: Normal

NCT ID: NCT01082315 Org: User:

Start: 04/30/09 End: 07/31/14 Due: 07/31/15

Trial With Cetuximab in Maintenance Therapy After Platinum Based Chemotherapy in First Line Treatment of Non-small Cell Lung Cancer (NSCLC)

Phase: N/A Priority: Normal

NCT ID: NCT00820755 Org: User:

Start: 01/31/09 End: 06/30/13 Due: 06/30/14

A Canadian, Multi-centre, Observational Registry to Study Adherence and Long Term Outcomes of Therapy in Pediatric Subjects Using SAIZEN® Via Easypod™ Auto-injector for Growth Hormone Treatment

Phase: N/A Priority: Normal

NCT ID: NCT01267526 Org: User:

Start: 05/31/11 End: 12/31/15 Due: 12/31/16

A Study to Evaluate Safety and Efficacy of Recombinant Human Luteinizing Hormone (r-hLH) Compared With Urinary Human Chorionic Gonadotrophin (u-hCG) to Trigger Ovulation in Infertile Women

Phase: N/A Priority: Normal

NCT ID: NCT01735422 Org: User:

Start: 12/31/99 End: 07/31/01 Due: 07/31/02

An Open-label Phase 4 Study to Explore Immunogenicity of the Liquid Formulation of Saizen® in Subjects With Adult Growth Hormone Deficiency (AGHD)

Phase: N/A Priority: Normal

NCT ID: NCT01806298 Org: User:

Start: 06/30/13 End: 03/31/16 Due: 03/31/17

An Observational Study to Examine the Patients With Isolated Systolic Hypertonia (ISH) Under Therapy With Eneas® (NIS ENEAS ISH)

Phase: N/A Priority: Normal

NCT ID: NCT01074281 Org: User:

Start: 06/30/08 End: 08/31/09 Due: 08/31/10

Saizen in Intra-uterine Growth Retardation

Phase: N/A Priority: Normal

NCT ID: NCT01400698 Org: User:

Start: 11/30/98 End: 02/28/10 Due: 02/28/11

Glucophage XR® Observational Study

Phase: N/A Priority: Normal

NCT ID: NCT01336673 Org: User:

Start: 06/30/11 End: 06/30/13 Due: 06/30/14

CONSORT Randomized Controlled Trial in Assisted Reproductive Technology

Phase: N/A Priority: Normal

NCT ID: NCT00829244 Org: User:

Start: 08/31/08 End: 01/31/10 Due: 01/31/11

Avelumab in Metastatic or Locally Advanced Solid Tumors (JAVELIN Solid Tumor JPN)

Phase: N/A Priority: Normal

NCT ID: NCT01943461 Org: User:

Start: 09/02/13 End: 09/25/19 Due: 09/25/20

Title	NCT ID	Organization	User	Status	Start Date	End Date	Reporting Due Date	Last Checked	User Role	Org Created
Non-interventional Study to Assess Adherence to Treatment for Patients With RMS (MAIN-MS)	NCT02921035	Merck KGaA, Darmstadt, Germany	user2@example.com	None	2016-06-30	2020-07-27	2021-07-27	-	-	2025-07-14
An Active-controlled, Clinical Trial to Assess Central Hemodynamic Effects of Bisoprolol in Hypertensive Patients (Central Hemodynamic Assessment Measured in Patient With HypertensION [CHAMPION])	NCT01079962	Merck KGaA, Darmstadt, Germany	user2@example.com	None	2009-12-31	2011-10-31	2012-10-31	-	-	2025-07-14
Pharmacokinetics in Subjects With Renal Impairment	NCT01504165	Merck KGaA, Darmstadt, Germany	user2@example.com	None	2012-01-31	2012-04-30	2013-04-30	-	-	2025-07-14
A Japanese Phase 1 Trial of TH-302 in Subjects With Solid Tumors and Pancreatic Cancer	NCT01833546	Merck KGaA, Darmstadt, Germany	user2@example.com	None	2013-04-18	2016-01-25	2017-01-25	-	-	2025-07-14
Transition to Rebif New Formulation	NCT00619307	Merck KGaA, Darmstadt, Germany	user2@example.com	None	2007-07-31	2008-04-30	2009-04-30	-	-	2025-07-14
Trial of MSC1936369B in Subjects With Solid Tumors	NCT00982865	Merck KGaA, Darmstadt, Germany	user2@example.com	None	2007-12-31	2016-04-30	2017-04-30	-	-	2025-07-14
REbif FLEXible Dosing in Early Multiple Sclerosis (MS)	NCT00404352	Merck KGaA, Darmstadt, Germany	user2@example.com	None	2006-11-30	2011-07-31	2012-07-31	-	-	2025-07-14
First-in-Human Trial of Anti-ADAMTS-5 Nanobody in Healthy Volunteers	NCT03224702	Merck KGaA, Darmstadt, Germany	user2@example.com	None	2017-09-04	2018-08-06	2019-08-06	-	-	2025-07-14
Long-term Follow-Up of Patients Who Participated in Study 27025 (REFLEX)	NCT00813709	Merck KGaA, Darmstadt, Germany	user2@example.com	None	2008-12-31	2013-09-30	2014-09-30	-	-	2025-07-14
Safety, Tolerability and Adherence With Rebif® New Formulation in Real Life Settings (STAR)	NCT01080027	Merck KGaA, Darmstadt, Germany	user2@example.com	None	2008-10-31	2011-06-30	2012-06-30	-	-	2025-07-14
Assessment of Patient Use of a New Device: RebiSmart	NCT01195870	Merck KGaA, Darmstadt, Germany	user2@example.com	None	2009-07-31	2010-10-31	2011-10-31	-	-	2025-07-14
A Trial to Evaluate the Correlation Between Spontaneous Catch-up Growth, Clinical Response to Saizen (Recombinant Human Growth Hormone, r-hGH) and Gene Expression Profiling in Children Small for Gestational Age (SGA)	NCT01067352	Merck KGaA, Darmstadt, Germany	user2@example.com	None	2004-02-29	2009-07-31	2010-07-31	-	-	2025-07-14
An Observational Study to Evaluate Quality of Life (QoL) and Influence of Cognitive Status on QoL in Patients With Relapsing-Remitting Multiple Sclerosis (RRMS) During 2 Years Treatment With Rebif New Formulation (RNF)	NCT01110993	Merck KGaA, Darmstadt, Germany	user2@example.com	None	2010-11-30	2013-09-30	2014-09-30	-	-	2025-07-14
Study of Tecemotide (L-BLP25) in Subjects With Slowly Progressive Multiple Myeloma With no Symptoms and Who Have Had no Chemotherapy	NCT01094548	Merck KGaA, Darmstadt, Germany	user2@example.com	None	2008-01-31	2012-03-31	2013-03-31	-	-	2025-07-14
Tolerability of Rebif® (Interferon-beta 1-A) Therapy in Korean Patients With Multiple Sclerosis	NCT01074346	Merck KGaA, Darmstadt, Germany	user2@example.com	None	2008-08-31	2011-11-30	2012-11-30	-	-	2025-07-14
A Korean Post-marketing Surveillance Study on Erbitux® in Patients With Metastatic Colorectal Cancer Refractory to Irinotecan-containing Treatment	NCT01082315	Merck KGaA, Darmstadt, Germany	user2@example.com	None	2009-04-30	2014-07-31	2015-07-31	-	-	2025-07-14
Trial With Cetuximab in Maintenance Therapy After Platinum Based Chemotherapy in First Line Treatment of Non-small Cell Lung Cancer (NSCLC)	NCT00820755	Merck KGaA, Darmstadt, Germany	user2@example.com	None	2009-01-31	2013-06-30	2014-06-30	-	-	2025-07-14
A Canadian, Multi-centre, Observational Registry to Study Adherence and Long Term Outcomes of Therapy in Pediatric Subjects Using SAIZEN® Via Easypod™ Auto-injector for Growth Hormone Treatment	NCT01267526	Merck KGaA, Darmstadt, Germany	user2@example.com	None	2011-05-31	2015-12-31	2016-12-31	-	-	2025-07-14
A Study to Evaluate Safety and Efficacy of Recombinant Human Luteinizing Hormone (r-hLH) Compared With Urinary Human Chorionic Gonadotrophin (u-hCG) to Trigger Ovulation in Infertile Women	NCT01735422	Merck KGaA, Darmstadt, Germany	user2@example.com	None	1999-12-31	2001-07-31	2002-07-31	-	-	2025-07-14
An Open-label Phase 4 Study to Explore Immunogenicity of the Liquid Formulation of Saizen® in Subjects With Adult Growth Hormone Deficiency (AGHD)	NCT01806298	Merck KGaA, Darmstadt, Germany	user2@example.com	None	2013-06-30	2016-03-31	2017-03-31	-	-	2025-07-14
An Observational Study to Examine the Patients With Isolated Systolic Hypertonia (ISH) Under Therapy With Eneas® (NIS ENEAS ISH)	NCT01074281	Merck KGaA, Darmstadt, Germany	user2@example.com	None	2008-06-30	2009-08-31	2010-08-31	-	-	2025-07-14
Saizen in Intra-uterine Growth Retardation	NCT01400698	Merck KGaA, Darmstadt, Germany	user2@example.com	None	1998-11-30	2010-02-28	2011-02-28	-	-	2025-07-14
Glucophage XR® Observational Study	NCT01336673	Merck KGaA, Darmstadt, Germany	user2@example.com	None	2011-06-30	2013-06-30	2014-06-30	-	-	2025-07-14
CONSORT Randomized Controlled Trial in Assisted Reproductive Technology	NCT00829244	Merck KGaA, Darmstadt, Germany	user2@example.com	None	2008-08-31	2010-01-31	2011-01-31	-	-	2025-07-14
Avelumab in Metastatic or Locally Advanced Solid Tumors (JAVELIN Solid Tumor JPN)	NCT01943461	Merck KGaA, Darmstadt, Germany	user2@example.com	None	2013-09-02	2019-09-25	2020-09-25	-	-	2025-07-14

Compliance Rate

My Organizations' Clinical Trials

Appearance